Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)

$54.01

 0.72 (1.35%)

High$54.27
Low$52.13
Volume786,242
Market Cap$7,589,293,519

09/30/16  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia 09/19/16

Read more

Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference 09/06/16

Read more

Events

Morgan Stanley Global Healthcare Conference09/13/16 9:10 a.m. ETView event2nd Quarter 2016 Financial Results07/26/16 4:30 p.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources